Mu and delta opioid receptors mediate opposite modulations by morphine of the spinal release of cholecystokinin-like material

[1]  G. Pasternak,et al.  An opiate-receptor gene family reunion , 1994, Trends in Neurosciences.

[2]  G. Pasternak,et al.  Modulation of Mu1 opioid binding by magnesium: evidence for multiple receptor conformations. , 1993, The Journal of pharmacology and experimental therapeutics.

[3]  M. Hamon,et al.  Opioid control of the release of calcitonin gene-related peptide-like material from the rat spinal cord in vivo , 1993, Brain Research.

[4]  J. Han,et al.  Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. , 1992, Neuroreport.

[5]  M. Laorden,et al.  Interaction of U-50,488H with calcium channel agonists and antagonists in different cardiac tissues. , 1992, Journal of autonomic pharmacology.

[6]  M. Hamon,et al.  KAPPA-/MU-receptor interactions in the opioid control of the in vivo release of substance P-like material from the rat spinal cord , 1992, Neuroscience.

[7]  M. Fournié-Zaluski,et al.  Stimulation of δ‐Opioid Receptors Reduces the In Vivo Binding of the Cholecystokinin (CCK)‐B‐Selective Agonist [3H]pBC 264: Evidence for a Physiological Regulation of CCKergic Systems by Endogenous Enkephalins , 1992, Journal of neurochemistry.

[8]  M. Hamon,et al.  GABA, acting at both GABAA and GABAB receptors, inhibits the release of cholecystokinin-like material from the rat spinal cord in vitro , 1992, Brain Research.

[9]  J. Levine,et al.  Antinociceptive and motor effects of delta/mu and kappa/mu combinations of intrathecal opioid agonists , 1992, Pain.

[10]  M. Hamon,et al.  Opioid Control of the In Vitro Release of Cholecystokinin‐Like Material from the Rat Substantia Nigra , 1992, Journal of neurochemistry.

[11]  M. Hamon,et al.  Cholecystokinin (CCK)-like material and CCK mRNA levels in the rat brain and spinal cord after acute or repeated morphine treatment , 1992, Neuropeptides.

[12]  M. Hamon,et al.  к-Opioid receptor stimulation abolishes μ- but not δ-mediated inhibitory control of spinal Met-enkephalin release , 1992, Neuroscience Letters.

[13]  D. Mayer,et al.  Spinal co-administration of cholecystokinin antagonists with morphine prevents the development of opioid tolerance , 1991, Pain.

[14]  H. Mosberg,et al.  Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.

[15]  K. Omote,et al.  δ receptor involvement in morphine suppression of noxiously evoked activity of spinal WDR neurons in cats , 1991, Brain Research.

[16]  P. Portoghese,et al.  Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.

[17]  L. Negri,et al.  Evidence for two subtypes of δ opioid receptors in rat brain , 1991 .

[18]  P. Contreras,et al.  Evaluation of U-50,488H analogs for neuroprotective activity in the gerbil , 1991, Brain Research.

[19]  M. Hamon,et al.  Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation , 1991, Neuroscience Letters.

[20]  J. Benoliel,et al.  Cholecystokinin-like immunoreactivity in the rat spinal cord: Effects of thoracic transection , 1991, Brain Research Bulletin.

[21]  A. Dickenson,et al.  Electrophysiologic studies on the spinal antinociceptive action of kappa opioid agonists in the adult and 21-day-old rat. , 1991, The Journal of pharmacology and experimental therapeutics.

[22]  R. Traub,et al.  Effects of spinal kappa-opioid receptor agonists on the responsiveness of nociceptive superficial dorsal horn neurons , 1991, Pain.

[23]  H. Mosberg,et al.  Opioid δ receptor subtypes are associated with different potassium channels , 1991 .

[24]  J. Benoliel,et al.  Cholecystokinin-like immunoreactivity in the dorsal horn of the rat spinal cord: an attempt to analyse contradictory results between immunocytochemistry and radioimmunoassay , 1990, Neuropeptides.

[25]  C. Alzheimer,et al.  Nonopioid actions of the kappa-opioid receptor agonists, U 50488H and U 69593 on electrophysiologic properties of hippocampal CA3 neurons in vitro. , 1990, The Journal of pharmacology and experimental therapeutics.

[26]  A. Carayon,et al.  Regional Distribution of Calcitonin Gene‐Related Peptide‐, Substance P‐, Cholecystokinin‐, Met5‐Enkephalin‐, and Dynorphin A (1–8)‐Like Materials in the Spinal Cord and Dorsal Root Ganglia of Adult Rats: Effects of Dorsal Rhizotomy and Neonatal Capsaicin , 1990, Journal of neurochemistry.

[27]  T. Hökfelt,et al.  PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Simonnet,et al.  Differential interactions of cholecystokinin and FLFQPQRF-NH2 with μ and δ opioid antinociception in the rat spinal cord , 1990, Neuropeptides.

[29]  P. Contreras,et al.  Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compounds , 1990, Brain Research.

[30]  J. Fujimoto,et al.  Spinal dynorphin A (1–17): Possible mediator of antianalgesic action , 1990, Neuropharmacology.

[31]  D. Mayer,et al.  Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment , 1990, Brain Research.

[32]  G. Pasternak,et al.  Proglumide selectively potentiates supraspinal μ1 opioid analgesia in mice , 1990, Neuropharmacology.

[33]  L. Tseng,et al.  Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice. , 1990, European journal of pharmacology.

[34]  D. Zimmerman,et al.  Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. , 1990, Journal of medicinal chemistry.

[35]  S. Iversen,et al.  The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. , 1990, European journal of pharmacology.

[36]  N. Baber,et al.  The role of CCK, caerulein, and CCK antagonists in nociception , 1989, Pain.

[37]  A. Takemori,et al.  Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice. , 1989, The Journal of pharmacology and experimental therapeutics.

[38]  R. Rodgers,et al.  Differential effects of the CCK antagonist, MK-329, on analgesia induced by morphine, social conflict (opioid) and defeat experience (non-opioid) in male mice , 1989, Neuropharmacology.

[39]  M. Sacristán,et al.  In vivo release of CCK‐8 from the dorsal horn of the rat: Inhibition by DAGOL , 1989, FEBS letters.

[40]  R. Freidinger.  Cholecystokinin and gastrin antagonists , 1989, Medicinal research reviews.

[41]  V. Hruby,et al.  [3H]-[H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.

[42]  J. Liebman,et al.  Antagonism of morphine analgesia by CCK-8-S does not extend to all assays nor all opiate analgesics , 1988, Peptides.

[43]  M. Rattray,et al.  The novel CCK antagonist L364,718 abolished caerulein- but potentiates morphine-induced antinociception. , 1988, European journal of pharmacology.

[44]  P. Portoghese,et al.  Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. , 1988, The Journal of pharmacology and experimental therapeutics.

[45]  R. Zukin,et al.  Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Iversen,et al.  Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. , 1988, European journal of pharmacology.

[47]  D. Menétrey,et al.  Neuropeptides in long ascending spinal tract cells in the rat: Evidence for parallel processing of ascending information , 1988, Neuroscience.

[48]  P. Portoghese,et al.  Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist , 1988 .

[49]  W. Zieglgänsberger,et al.  Dynorphin1–17 reduces the inhibitory actions of μ-and δ-selective opioid agonists in cortical neurons of the rat in vivo , 1988, Neuroscience Letters.

[50]  P. Portoghese,et al.  Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice. , 1987, The Journal of pharmacology and experimental therapeutics.

[51]  R. Hill,et al.  CCK 8 analgesia and hyperalgesia after intrathecal administration in the rat: Comparison with CCK-related peptides , 1987, Neuropeptides.

[52]  P. Mantegazza,et al.  Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin , 1987, Brain Research.

[53]  R. Hill,et al.  Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: Effects of naloxone and peptidase inhibitors , 1987, Neuropharmacology.

[54]  A. Dickenson,et al.  Antagonism of μ-opioid receptor-mediated inhibitions of nociceptive neurones by U50488H and dynorphin A1–13 in the rat dorsal horn , 1987, Neuroscience Letters.

[55]  M. Hamon,et al.  Opposite Effects of δ and μ Opioid Receptor Agonists on the In Vitro Release of Substance P‐Like Material from the Rat Spinal Cord , 1987 .

[56]  J. Besson,et al.  Peripheral and spinal mechanisms of nociception. , 1987, Physiological reviews.

[57]  J. Liebman,et al.  Antinociceptive profile of sulfated CCK-8 Comparison with CCK-4, unsulfated CCK-8 and other neuropeptides , 1986, Neuropharmacology.

[58]  L. Watkins,et al.  Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide , 1985, Brain Research.

[59]  L. Watkins,et al.  Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates , 1985, Brain Research.

[60]  S. Itoh,et al.  Potentiation of β-endorphin effects by proglumide in rats , 1985 .

[61]  G. Tramu,et al.  Cholecystokinin-like immunoreactivity in the dorsal horn of the spinal cord of the rat: A light and electron microscopic study , 1984, Neuroscience.

[62]  M. Iadarola,et al.  Proglumide prevents and curtails acute tolerance to morphine in rats , 1984, Neuropharmacology.

[63]  R. Maciewicz,et al.  Edinger-Westphal nucleus: cholecystokinin immunocytochemistry and projections to spinal cord and trigeminal nucleus in the cat , 1984, Brain Research.

[64]  L. Watkins,et al.  Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. , 1984, Science.

[65]  B. Roques,et al.  Deltakephalin, Tyr-D-Thr-Gly-Phe-Leu-Thr: a new highly potent and fully specific agonist for opiate delta-receptors. , 1983, Biochemical and biophysical research communications.

[66]  L. Watkins,et al.  Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. , 1983, Science.

[67]  J. Morley,et al.  Selective antagonists at the opiate delta-receptor. , 1982, Life sciences.

[68]  V. Go,et al.  Studies on the location and release of cholecystokinin and vasoactive intestinal peptide in rat and cat spinal cord , 1982, Brain Research.

[69]  S. Itoh,et al.  Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat , 1982 .

[70]  H. Loh,et al.  Possible regulatory role of dynorphin on morphine- and beta-endorphin-induced analgesia. , 1981, The Journal of pharmacology and experimental therapeutics.

[71]  G. Zetler,et al.  Antinociceptive effect of centrally administered caerulein and cholecystokinin octapeptide (CCK-8)☆ , 1981 .

[72]  B. Morgan,et al.  Analogues of β-LPH61–64 posessing selective agonist activity at μ-opiate receptors , 1981 .

[73]  G. Zetler.  Analgesia and ptosis caused by caerulein and cholecystokinin octapeptide (CCK-8) , 1980, Neuropharmacology.